Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

about

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

P2860

Q57147396-2687A6F4-D7BF-425E-94DD-58B430E900FE

P2860

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q40498036

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Crystal digital droplet PCR fo ...... ed non-small cell lung cancer.

@en

type

Item

label

Crystal digital droplet PCR fo ...... ed non-small cell lung cancer.

@en

prefLabel

Crystal digital droplet PCR fo ...... ed non-small cell lung cancer.

@en

P1476

Crystal digital droplet PCR fo ...... ed non-small cell lung cancer.

@en

P2093

Aurélie Honoré

http://www.w3.org/2001/XMLSchema#string

Barbara André

http://www.w3.org/2001/XMLSchema#string

Benjamin Besse

http://www.w3.org/2001/XMLSchema#string

Etienne Rouleau

http://www.w3.org/2001/XMLSchema#string

Jordan Madic

http://www.w3.org/2001/XMLSchema#string

Jordi Remon

http://www.w3.org/2001/XMLSchema#string

Ludovic Lacroix

http://www.w3.org/2001/XMLSchema#string

Magali Droniou

http://www.w3.org/2001/XMLSchema#string

Romain Girard

http://www.w3.org/2001/XMLSchema#string

P2860

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Circulating mutant DNA to assess tumor dynamics

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Circulating tumor DNA as a liquid biopsy for cancer.

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.

P304

e0183319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0183319

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cécile Jovelet

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28829811

http://www.w3.org/2001/XMLSchema#string

P932

5567481

http://www.w3.org/2001/XMLSchema#string

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

about

P2860

P2860

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932